Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-03-26
DOI
10.3389/fphar.2021.646676
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2
- (2021) Tianling Ou et al. PLoS Pathogens
- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
- (2020) Manli Wang et al. CELL RESEARCH
- Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR
- (2020) Victor M Corman et al. Eurosurveillance
- Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
- (2020) Peter Richardson et al. LANCET
- Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
- (2020) Nanshan Chen et al. LANCET
- COVID-19: combining antiviral and anti-inflammatory treatments
- (2020) Justin Stebbing et al. LANCET INFECTIOUS DISEASES
- Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods
- (2020) Canrong Wu et al. Acta Pharmaceutica Sinica B
- Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
- (2020) Sangeun Jeon et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2
- (2020) Vanessa Monteil et al. CELL
- Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection
- (2020) Jacques Fantini et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
- (2020) Philippe Gautret et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- A Review of SARS-CoV-2 and the Ongoing Clinical Trials
- (2020) Yung-Fang Tu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Remdesivir for the Treatment of Covid-19 — Preliminary Report
- (2020) John H. Beigel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Compassionate Use of Remdesivir for Patients with Severe Covid-19
- (2020) Jonathan Grein et al. NEW ENGLAND JOURNAL OF MEDICINE
- Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
- (2020) Xiuyuan Ou et al. Nature Communications
- Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro
- (2020) Jia Liu et al. Cell Discovery
- The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro
- (2020) Leon Caly et al. ANTIVIRAL RESEARCH
- Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19
- (2020) Samia Arshad et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study
- (2020) Abdo A. Elfiky LIFE SCIENCES
- Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2
- (2020) Brandi N. Williamson et al. NATURE
- Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing
- (2020) Laura Riva et al. NATURE
- Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates
- (2020) Pauline Maisonnasse et al. NATURE
- Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19
- (2020) Alexandre B. Cavalcanti et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
- (2020) David R. Boulware et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
- (2020) Jérôme Hadjadj et al. SCIENCE
- Potential Antiviral Options against SARS-CoV-2 Infection
- (2020) Aleksandr Ianevski et al. Viruses-Basel
- From SARS to MERS, Thrusting Coronaviruses into the Spotlight
- (2019) Zhiqi Song et al. Viruses-Basel
- Arbidol (Umifenovir): A Broad-Spectrum Antiviral Drug That Inhibits Medically Important Arthropod-Borne Flaviviruses
- (2018) Jan Haviernik et al. Viruses-Basel
- Ebola Virus and Severe Acute Respiratory Syndrome Coronavirus Display Late Cell Entry Kinetics: Evidence that Transport to NPC1+Endolysosomes Is a Rate-Defining Step
- (2015) Rebecca M. Mingo et al. JOURNAL OF VIROLOGY
- Development of novel entry inhibitors targeting emerging viruses
- (2012) Yanchen Zhou et al. Expert Review of Anti-Infective Therapy
- Severe Acute Respiratory Syndrome Coronavirus Replication Is Severely Impaired by MG132 due to Proteasome-Independent Inhibition of M-Calpain
- (2012) Martha Schneider et al. JOURNAL OF VIROLOGY
- Fast gapped-read alignment with Bowtie 2
- (2012) Ben Langmead et al. NATURE METHODS
- Azithromycin induces anti-viral responses in bronchial epithelial cells
- (2010) V. Gielen et al. EUROPEAN RESPIRATORY JOURNAL
- The Sequence Alignment/Map format and SAMtools
- (2009) H. Li et al. BIOINFORMATICS
- Lipid rafts are involved in SARS-CoV entry into Vero E6 cells
- (2008) Yanning Lu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now